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Objective: A restrictive use of tricyclic antidepressants (TCA) in patients with dementia 
(PwD) is recommended due to the hazard of anticholinergic side effects. We evaluated 
the frequency of TCA dispensing in PwD over a period of 1 year and the use of TCA 
before and after the incident diagnosis of dementia.
Methods: This analysis was based on administrative data from a German statutory health 
insurance for a period of 2 years. Totally, 20,357 patients with an incident diagnosis of 
dementia in 2014 were included. We evaluated the dispensing of TCA in 2015. Subgroup 
analyses were conducted to evaluate associations between the incident diagnosis of 
dementia and modifications in TCA dispensing.
Results: In 2015, 1,125 dementia patients (5.5%) were treated with TCA and 31% were 
medicated with TCA in all four quarters of 2015. Most dispensings were conducted by 
general practitioners (67.9%). On average, patients received 3.7 ± 2.6 dispensings per 
year. Amitriptyline (56.3%), doxepin (26.8%), and trimipramine (16.8%) were dispensed 
most often. Subgroup analyses revealed that the dispensing of TCA remained mainly 
unchanged following the incident diagnosis.
Conclusion: A relevant number of PwD were treated with TCA. To maintain the patients’ 
safety, an improved implementation of guidelines for the pharmaceutical treatment of 
PwD in healthcare institutions might be required. Since 68% of the patients suffered from 
depression, future studies should further evaluate the indications for TCA.
Keywords: antidepressants, tricyclic, claims data, dementia, pharmacotherapy
INTRODUCTION
Patients with dementia (PwD) frequently experience comorbid psychiatric disorders like depression, 
anxiety, and sleep disturbances (Enache et al., 2011; Mortamais et al., 2018). Randomized controlled 
trials suggest that antidepressants can be effective in treating depression in PwD, although the 
evidence is inconclusive and there is no evidence of superior efficacy of any particular antidepressant 
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(Dudas et al., 2018). Certain antidepressants can also be used 
for symptoms like sleep disturbances, anxiety, and restlessness 
(McCurry et al., 2005). However, the German guideline for the 
treatment of PwD does not contain specific pharmacological 
recommendations for the treatment of comorbid sleep disorders 
or anxiety in PwD (Deuschl and Maier, 2016).
From a neurochemical perspective, the bioavailability 
of several neurotransmitters is diminished in PwD. This 
is especially apparent in Alzheimer’s disease (AD), where 
the reduced availability of acetylcholine and consequent 
dysfunctions of the cholinergic system are considered essential 
factors in the occurrence of typical AD symptoms (Pinto et al., 
2011). Unfortunately, anticholinergic side effects are often seen 
in patients using tricyclic antidepressants (TCAs), leading to an 
increased risk of further cognitive decline, tachycardia, epileptic 
seizures, delirium, and urinary retention (Patel et al., 2017). 
TCAs might also increase the risk of impaired coordination and 
fall due to their sedative effects (O’Neil et al., 2018). Current 
guidelines therefore recommend a restrictive use of TCA in PwD 
(Deuschl and Maier).
Previous studies have examined the dispensing of 
antidepressant drugs using either primary databases or claims data 
(Arbus et al., 2010; Majic et al., 2010; Rapp et al., 2010; Wetzels 
et al., 2011; Martinez et al., 2013; Taipale et al., 2014; Giebel et al., 
2015; Laitinen et al., 2015; Booker et al., 2016; Breining et al., 2016; 
David et al., 2016; Jacob et al., 2017; Jobski et al., 2017; Puranen 
et al., 2017). However, the specific dispensing of TCAs have not 
yet been analyzed using claims data of the German healthcare 
system. This information about TCA dispensing behavior would 
be important for health care providers regarding patients’ safety 
and guideline-adherent pharmacotherapy (Holt et al., 2010).
The aim of our study was therefore to evaluate the frequency 
of TCA dispensing over a period of 1 year. In particular, this 
analysis illustrates how often TCAs were dispensed to PwD over 
a period of 12 months by evaluating the number of quarters in 
2015 with at least one TCA dispensing per patient. Second, we 
included PwD who were diagnosed with dementia for the first 
time in the previous year (2014), which allowed us to detect 
modifications of TCA dispensing during those 12 months 
after the incident diagnosis of dementia. We hypothesized that 
physicians avoid dispensing TCAs after a dementia diagnosis 
owing to their adherence to current guidelines. To the best of our 
knowledge, this is the first evaluation using claims data to analyze 
the dispensing of TCAs for PwD in Germany.
PATIENTS AND METHODS
For this observational cohort study, we used anonymized claims 
data from the years 2014 and 2015, provided by a large German 
statutory health insurance fund (Allgemeine Ortskrankenkasse 
Niedersachsen, AOK). The local research ethics committee at the 
University Medical Center Goettingen, Germany, confirmed that 
the project is exempt from the requirement of a regular review by 
the committee because all data were anonymized.
We included patients who were diagnosed with dementia 
for the first time in 2014, based on diagnostic criteria of the 
International Classification of Diseases (ICD-10-GM codes 
F00.0, F00.1, F00.2, F00.9, F01.0, F01.1, F01.2, F01.3, F01.8, F01.9, 
F02.0, F02.3, F03, G30.0, G30.1, G30.8, G30.9, G31.0, G31.82) 
(International Classification of Diseases, 2018). To be eligible, 
patients had i) to be ≥65 years at the beginning of 2014, ii) to be 
continuously insured in 2014 and 2015, and iii) no diagnosis of 
dementia in the year before the new diagnosis. To confirm a 
subsequent diagnosis of dementia in the dataset, dementia had 
to be encoded again at least once (inpatient main or secondary 
diagnosis) or twice in two different quarters (confirmed 
outpatient diagnosis) over a period of 12 months after the 
first codification (Lange et al., 2015). TCAs were identified 
in the claims data according to the Anatomical Therapeutic 
Chemical Classification.
We evaluated the frequency of TCA dispensing in 2015 
according to the prescription dates. For this 12-month 
observation period, we examined the total number of patients 
treated with at least one TCA dispensing. Additionally, we 
evaluated for how many quarters of 2015 (one, two, three, or all 
four quarters) a TCA dispensing was registered for each patient 
and which specialist dispensed the TCA. Furthermore, the 
dispensing of TCAs before and after the diagnosis of dementia 
was analyzed. Patients who were first diagnosed with dementia 
either in the third or the fourth quarter of 2014 were selected, and 
the dispensing of TCAs was evaluated two quarters before and 
four quarters after the incident diagnosis. A detailed description 
of the methods applied is given in a recently published study 
(Hessmann et al., 2018).
This study aimed at descriptively analyzing dementia patients’ 
treatment with TCAs. Data are presented as total numbers of 
cases and percentages or as means with standard deviations 
(SD), median, minimum, and maximum. All statistical analyses 
were conducted with Microsoft Office Excel 2010 (Microsoft 
Corporation, Redmond, USA) and SPSS Version 24.0 (IBM SPSS 
Statistics, Armonk, USA). Significance was defined as α = 0.05, 
and the normal distribution was assessed with the Kolmogorov–
Smirnov test before conducting bivariate analyses. Friedman 
tests and Cochran’s Q tests were used to examine whether TCA 
dispensing differs before and after diagnosis of dementia.
RESULTS
The study sample was derived from a cohort of 23,232 persons 
who were registered as incident PwD for the year 2014 in claims 
data of the AOK Niedersachsen. We excluded 2,875 patients 
who were below 65 years of age at the beginning of 2014 and/
or who were not constantly insured during 2014 and 2015. 
The remaining 1,125 participants (5.5%) had at least one TCA 
dispensing in 2015 (77.4% females, n = 871) and were 80.5 ± 6.9 
years (median = 80.0). The majority (75.6%, n = 851) had already 
received a TCA in 2014, while for 24.4%, the first TCA dispensing 
was encoded in 2015. Depressive syndromes (monophasic or 
recurrent) were encoded for 764 patients (67.9%) in our cohort. 
As shown in Figure 1A, patients were most often treated with 
amitriptyline (56.3%, n = 633), doxepin (26.8%, n = 302), and 
trimipramine (16.8%, n = 189).
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In 2015, patients had 3.7 ± 2.6 (median = 3.0) dispensings 
of TCA on average, with an average of 4.0 ± 3.2 (median = 
3.0) dispensings for doxepin, while patients with amitriptyline 
received 3.5 ± 2.3 (median = 3.0) and those with trimipramine 
received 3.0 ± 2.0 (median = 3.0) dispensings. Of the total 
4,914 TCA dispensings in 2015, most dispensings were made 
by general practitioners (n = 3,336, 67.9%), while specialists in 
internal medicine were responsible for 822 (16.7%) dispensings, 
and psychiatrists and neurologists for 660 (13.4%).
Next, we examined the number of quarters in 2015 with at 
least one TCA dispensing per patient (Figure 1B). Totally, 31.0% 
(n = 349) of the patients received a dispensing in all four quarters, 
while 24.9% (n = 281) patients received a TCA in one or three 
quarters, and 19.0% (n = 214) had dispensings in two quarters. 
Most patients treated with trimipramine (32.1%, n = 61) received 
dispensings in only one quarter, while doxepin was dispensed 
over all four quarters for the majority (37.1%, n = 112). However, 
dispensings in two quarters were less often seen, especially in the 
case of amitriptyline (18.0%, n = 114).
Finally, we evaluated whether the dispensing of TCAs 
was associated with the incident diagnosis of dementia. 
We conducted subgroup analyses in those patients with an 
FIGURE 1 | Total number of patients with at least one dispensing of tricyclic antidepressants (TCA) in 2015 (A) and frequency (%) of TCA dispensing in 2015 (B).
Dispensing of Tricyclic Antidepressants in DementiaHessmann et al.
4 July 2019 | Volume 10 | Article 841Frontiers in Pharmacology | www.frontiersin.org
incident diagnosis in the third or fourth quarter of 2014 who 
were already treated with TCAs over a period of two quarters 
prior to the incident diagnosis (30.1%, n = 339). Specifically, 
TCA dispensings among the selected patients were evaluated 
for two quarters before and four quarters after the incident 
dementia diagnosis. The number of patients receiving TCAs 
diminished following the incident diagnosis, although this was 
not significant, and no differences in the dispensing frequencies 
of TCAs were seen. A distinguished analysis of the dispensing 
of each substance also showed no trend towards a diminished 
dispensing of TCAs, except for doxepin (Table 1). However, 
after adjusting for multiple testing differences in the dispensing 
of doxepin did not remain significant.
DISCUSSION
In addition to earlier studies exploring the use of antidepressant 
drugs among PwD in general (Martinez et al., 2013; Taipale 
et al., 2014; David et al., 2016; Jacob et al., 2017), this paper 
specifically focuses on the dispensing of TCA in PwD based on 
German healthcare claims data. In our study cohort, 5.5% of 
those patients who were diagnosed with dementia for the first 
time in 2014 were treated with TCA, while about one third of 
TCA users did not have a diagnosis of depression. According to 
international guidelines, TCA should be avoided in PwD due 
to the risk of anticholinergic side effects (Deuschl and Maier). 
Therefore, the results of our study underline the importance 
of a well-considered pharmaceutical treatment of PwD. 
Additionally, the appropriate implementation of guidelines 
for the treatment of PwD in healthcare institutions should be 
further evaluated.
Generally, the use of different databases (primary vs. claims 
data), the included types of dementia, and divergent sample 
sizes complicate comparisons with earlier studies. Nevertheless, 
earlier studies in Germany reported antidepressant dispensing 
rates of about 19 to 47% in PwD (Majic et al., 2010; Giebel et al., 
2015).  These findings are comparable with European studies 
determining utility rates of antidepressants of 13 to 40% (Laitinen 
et al., 2015; Breining et al., 2016). However, the use of TCA was not 
explicitly evaluated in the majority of earlier studies. Therefore, 
further studies on the use of TCA would be relevant to assess 
whether a dispensing rate of 5.5% in PwD is comparable to other 
samples. In case, further studies report that considerably lower 
dispensing rates would be highly important to evaluate reasons 
for a lower use of TCA. Implementing methods to diminish the 
use of TCA could contribute to the patients’ safety and guideline-
adherent treatment.
In our study, TCAs were dispensed most often by general 
practitioners. This contradicts other studies which showed 
that PwD who were seen by specialists (psychiatrists or 
neurologists) had a considerably higher chance of being treated 
with antidepressants in general (Rapp et al., 2010; Hessmann 
et al., 2018).
In Germany, claims data do not contain details on indications 
for the dispensing of certain substances. Our data therefore 
do not allow for direct conclusions about the appropriateness 
of TCA dispensing regarding different indications such as 
depression, anxiety disorders, sleep disturbances, or chronic 
pain syndrome, but it can provide clues on potentially 
inappropriate use of TCAs. In a prospective study, Wetzels 
et al. reported that more than 60% of PwD living in nursing 
homes received antidepressants over a period of 2 years, 
although depressive symptoms were not observed for many 
of these patients during clinical examination (Wetzels et al., 
2011). However, some authors also suggest that antidepressants 
may be under-used in PwD. Giebel et al. showed that less than 
half of all PwD with clinically relevant depression received 
antidepressant drugs (Giebel et al., 2015).
The specific indications for TCA in PwD should be evaluated 
in future studies to understand the medical background of the 
dispensing. For this purpose, the attending physicians should 
be directly involved, e.g., using standardized questionnaires or 
qualitative interviews. Nevertheless, the relatively high number 
of PwD with a comorbid depression of about 67% might be the 
most likely reason for the dispensing of TCAs. Furthermore, the 
TABLE 1 | Dispensing of tricyclic antidepressants (TCA) over two quarters before and four quarters after the diagnosis of dementia in Q3 or Q4 of 2014 (n = 339).
Two quarters 
before Dx
One quarter 
before Dx
Quarter of Dx One quarter 
after Dx
Two quarters 
after Dx
Three quarters 
after Dx
p value
TCA total (n, %)
Mean ± SD
Median (range)
271 (79.9)
1.50 ± 0.89
1 (1–7)
275 (81.1)
1.42 ± 0.75
1 (1–7)
266 (78.5)
1.54 ± 0.85
1 (1–7)
264 (77.9)
1.44 ± 0.87
1 (1–8)
259 (76.4)
1.43 ± 0.80
1 (1–7)
254 (74.9)
1.37 ± 0.72
1 (1–7)
p = 0.305
p = 0.090
Amitriptyline (n, %)
Mean ± SD
Median (range) 
150 (44.2)
1.43 ± 0.79
1 (1–5)
150 (44.2)
1.46 ± 0.72
1 (1–4)
152 (44.8)
1.46 ± 0.75
1 (1–4)
151 (44.5)
1.40 ± 0.73
1 (1–5)
153 (45.1)
1.34 ± 0.64
1 (1–4)
147 (43.4)
1.29 ± 0.62
1 (1–4)
p = 0.981
p = 0.178
Doxepin (n, %)
Mean ± SD
Median (range)
84 (24.8)
1.53 ± 0.97
1 (1–7)
75 (22.1)
1.45 ± 0.91
1 (1–7)
70 (20.6)
1.63 ± 1.07
1 (1–7)
72 (21.2)
1.56 ± 1.16
1 (1–8)
61 (18.0)
1.62 ± 1.14
1 (1–7)
62 (18.3)
1.50 ± 0.90
1 (1–7)
p = 0.016
p = 0.585
Trimipramine (n, %)
Mean ± SD
Median (range)
40 (11.8)
1.48 ± 0.59
1 (1–3)
41 (12.1)
1.22 ± 0.53
1 (1–3)
37 (10.9)
1.46 ± 0.73
1 (1–3)
34 (10.0)
1.26 ± 0.57
1 (1–3)
38 (11.2)
1.37 ± 0.59
1 (1–3)
38 (11.2)
1.32 ± 0.62
1 (1–3)
p = 0.667
p = 0.257
TCA total (n, %), Number of patients with at least one dispensing of TCAs in the respective quarter; Mean ± SD, Average number of TCA dispensings in the respective quarter; 
Median (Range), Median number of TCA dispensings in the respective quarter; Quarter of Dx, Quarter 3 or 4 in 2014 when dementia was diagnosed; SD, standard deviation; 
p-value according to Friedman-tests and Cochran’s Q-tests.
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frequency of dispensing varied between the different TCAs. For 
example, trimipramine was dispensed in only one quarter during 
the study period by majority. This might be associated with the 
common use of trimipramine for sleeping disorders which do 
not necessarily have to be treated permanently.
LIMITATIONS
Although the effective study sample consisted of more than 
20,000 patients, our data do not cover the dispensing of TCAs 
for the entire German population of PwD. Another limitation 
concerns the diagnostic codes in claims data which are encoded. 
In particular, only those medical conditions fulfilling the 
diagnostic criteria according to the ICD-10-GM (e.g., major 
depression) are registered by the attending physicians. In contrast, 
disorders not fulfilling these criteria are usually not encoded. 
This is especially important for the evaluation of indications for 
TCAs, which are also dispensed as symptomatic treatment for 
certain psychiatric disturbances (e.g., sleep disorders, anxiety). 
Therefore, drawing conclusions about the appropriateness of a 
TCA dispensing based on claims data is generally limited and 
additional clinical information is required. In addition, more 
detailed analyses on the number of dispensings as well as the 
defined daily doses in each quarter are planned on the basis of 
these claims data.
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